A medical devices company launching an FDA-approved miniaturized polymerase chain reaction (“PCR”) diagnostic testing device for the detection of infectious diseases.​

Visby has developed an instrument-free PCR based diagnostic testing device designed for the detection of respiratory and sexually-transmitted infections (STI). The key innovation is the device design, allowing for instrument-free PCR testing without the use of a laboratory, while still delivering lab-grade accuracy. The design results in a portable and lower-cost PCR testing option delivering results in ~30 minutes, significantly faster than lab testing. Proceeds will be used to fund Visby’s GTM strategy to penetrate new healthcare systems / channel partners and the commercial launch of an at-home testing device.